Tus kws kho mob
BlueRide Incident Report Form
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 2241 - 2250 ntawm 4139
Tus kws kho mob
QP41-21 Commercial and MHCP Pharmacy Benefit Exclusion for Qutenza®
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 12, 2021
Tus kws kho mob
QP42-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hemophilia Agents
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 12, 2021
Tus kws kho mob
QP2-21 Update for New to Market Medical Drugs: Aducanumab, Casimersen, Evinacumab, Idecabtagene Vicleucel, and Pegunigalsidase Alfa
Hnub Tim pib siv tau lub khoos kas: Lub Ib Hlis Ntuj 13, 2021
Tus kws kho mob
Transportation Services Level of Need
Tus kws kho mob
Upcoming Policies Effective July 5, 2021
Tus kws kho mob
P29-21 Reimbursement Change for Licensed Professional Clinical Counselors (LPCC)
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 03, 2021
Tus kws kho mob
P21-21 RAP Claims Required for Home Care Claims Effective July 1, 2021
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 03, 2021
Tus kws kho mob
P26-21 Sequestration Suspension for Medicare Lines of Business Extended
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 03, 2021
Tus kws kho mob
P32-21 eviCore Healthcare Specialty Utilization Management (UM) Program – Musculoskeletal Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 03, 2021